Jasper Therapeutics Inc. (JSPR)
NASDAQ: JSPR
· Real-Time Price · USD
5.55
-0.08 (-1.42%)
At close: Jun 17, 2025, 12:52 PM
-1.42% (1D)
| Bid | 5.54 |
| Market Cap | 83.37M |
| Revenue (ttm) | 1.17M |
| Net Income (ttm) | 13.73M |
| EPS (ttm) | -5.27 |
| PE Ratio (ttm) | -1.05 |
| Forward PE | -1.1 |
| Analyst | Buy |
| Ask | 5.64 |
| Volume | 64,004 |
| Avg. Volume (20D) | 196,482 |
| Open | 5.61 |
| Previous Close | 5.63 |
| Day's Range | 5.51 - 5.64 |
| 52-Week Range | 3.13 - 26.05 |
| Beta | 2.73 |
About JSPR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol JSPR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for JSPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
-60.53%
Jasper Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
6 months ago
-1.46%
Jasper Therapeutics shares are trading higher after the company announced it dosed its first patient in its Phase 1b/2a EESIAN study evaluating Briquilimab.
7 months ago · seekingalpha.com
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And AsthmaJasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved...